Heyu Biological Technology (OTCMKTS:HYBT – Get Free Report) and NeurAxis (NASDAQ:NRXS – Get Free Report) are both small-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.
Valuation and Earnings
This table compares Heyu Biological Technology and NeurAxis’ revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Heyu Biological Technology | $80,000.00 | 322.65 | -$270,000.00 | N/A | N/A |
NeurAxis | $2.27 million | 9.33 | -$14.63 million | ($3.73) | -0.85 |
Heyu Biological Technology has higher earnings, but lower revenue than NeurAxis.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Heyu Biological Technology | -453.55% | -6.43% | -4.43% |
NeurAxis | -633.10% | N/A | -926.02% |
Analyst Ratings
This is a summary of current ratings for Heyu Biological Technology and NeurAxis, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Heyu Biological Technology | 0 | 0 | 0 | 0 | N/A |
NeurAxis | 0 | 0 | 1 | 0 | 3.00 |
Insider and Institutional Ownership
11.8% of NeurAxis shares are owned by institutional investors. 89.2% of Heyu Biological Technology shares are owned by insiders. Comparatively, 15.2% of NeurAxis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Heyu Biological Technology beats NeurAxis on 5 of the 9 factors compared between the two stocks.
About Heyu Biological Technology
Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.
About NeurAxis
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Receive News & Ratings for Heyu Biological Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heyu Biological Technology and related companies with MarketBeat.com's FREE daily email newsletter.